CancerDrs

Colorectal Cancer clinical trials in Illinois

44 actively recruiting colorectal cancer trials at 71 sites across Illinois.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Advocate Outpatient Center - Aurora — Aurora, Illinois
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • Memorial Hospital of Carbondale — Carbondale, Illinois
  • SIH Cancer Institute — Carterville, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …

Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Illinois:
  • Illinois Cancer Specialists — Arlington Heights, Illinois
  • Illinois CancerCare - Bloomington — Bloomington, Illinois
  • Illinois Cancer Specialists — Chicago, Illinois
  • Illinois CancerCare - Galesburg — Galesburg, Illinois
  • Hope and Healing Cancer Services — Hinsdale, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Illinois:
  • Rush-Copley Medical Center — Aurora, Illinois
  • Northwestern University — Chicago, Illinois
  • Carle at The Riverfront — Danville, Illinois
  • Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
  • Carle Physician Group-Effingham — Effingham, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Illinois:
  • Illinois Cancer Specialists — Arlington Heights, Illinois
  • Illinois CancerCare — Peoria, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
  • University of Chicago Comprehensive Cancer Center — Chicago, Illinois
  • Memorial Hospital East — Shiloh, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…

Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Illinois:
  • Clinical Study Site — Chicago, Illinois
  • Clinical Study Site — Elmhurst, Illinois
  • Clinical Study Site — O'Fallon, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…

Sponsor: Amgen
NCT ID: NCT06252649
Sites in Illinois:
  • Insight Research Institute — Chicago, Illinois
  • Hope and Healing Cancer Services — Hinsdale, Illinois
  • Orchard Healthcare Research Inc — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Illinois:
  • Hope and Healing Cancer Services — Hinsdale, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Colorectal Cancer Undergoing Chemotherapy

This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed locally advanced, unresectable or metastatic colorectal cancer. This study w…

Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Illinois:
  • Investigative Site — Chicago, Illinois
  • Investigative Site — Hinsdale, Illinois
  • Investigative Site — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metasta…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691491
Sites in Illinois:
  • Memorial Hospital East — Shiloh, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…

Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Illinois:
  • University of Chicago Medical Center /ID# 274742 — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Illinois:
  • Orchard Healthcare Research Inc. — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…

Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Illinois:
  • University of Chicago Medical Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery

A single arm, prospective, single center Phase1/2 Dietary intervention trial for subjects diagnosed with colorectal cancer and scheduled for tumor resection more than 21 days from informed consent. Subjects will be provided 21 days of stan…

Sponsor: University of Chicago
NCT ID: NCT06349590
Sites in Illinois:
  • University of Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby …

Sponsor: Northwestern University
NCT ID: NCT05733000
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Illinois:
  • Exelixis Clinical Site #26 — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Illinois:
  • University of Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other pl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05803382
Sites in Illinois:
  • Memorial Hospital East — Shiloh, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and …

Sponsor: Xencor, Inc.
NCT ID: NCT05433142
Sites in Illinois:
  • Xencor Investigative Site — Chicago, Illinois
  • Xencor Investigative Site — Chicago, Illinois
View on ClinicalTrials.gov →

Showing 25 of 44 trials with sites in Illinois. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15